Partnership formed to counter CBRN

• Tweet

ROCKVILLE, Md., June 19 (UPI) -- A public-private partnership was formed by Emergent BioSolutions Inc. and a U.S. government authority for CBRN countermeasures and influenza vaccine production.

Emergent BioSolutions said its Maryland facility will be used for the program with the Biomedical Advanced Research and Development Authority -- a unit within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services -- for the center of innovation under the $220 million shared-cost contract for the development of chemical, biological, radiological and nuclear medical countermeasures.

"Emergent is pleased to enter into this long-term public-private partnership with BARDA to help achieve our common goal of strengthening national security and preparedness efforts," said Daniel J. Abdun-Nabi, president and chief executive officer of Emergent BioSolutions.

"We are honored by the U.S. government's continued confidence in us, which is founded on our longstanding track record of being the premier biodefense developer and supplier of medical countermeasures."

The contract has an eight-year period of performance. There are also 17 one-year options.